Skip to content

US · LITS · BIOTECHNOLOGY

Lite Strategy, Inc. (LITS) intrinsic value and stock valuation

$0.80as of 2026-11-21 · Mkt cap 30.88M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lite Strategy, Inc. DCF and intrinsic value

InvestorsCraft values LITS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LITS’s statements →

Lite Strategy, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 litestrategy.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-15.95M
20212025
Free cash flow
-$-20.84M
20212025
Total equity
$16.9M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$65.3M$48.8M$40.7M$34.8M
Operating income-$-17.45M$14.5M-$-36.76M-$-75.48M-$-60.42M
Net income-$-15.95M$17.8M-$-31.84M-$-54.45M-$-41.31M
EPSd-$-2.39M$2.67M-$-4.78M-$-8.7M-$-7.22M
Operating cash flow-$-20.84M-$-50.47M-$-52.48M-$-48.75M-$-31.96M
Capital expenditure$0.00-$-10K-$-40K-$-480K-$-710K
Free cash flow-$-20.84M-$-50.48M-$-52.52M-$-49.23M-$-32.67M
Total assets$18.3M$41.4M$120.8M$177.8M$174.1M
Total debt$0.00$0.00$12.7M$9.64M$8.3M
Net debt-$-18.01M-$-3.71M-$-4.18M-$-6.1M-$-240K
Total equity$16.9M$33M$24.6M$52.4M$49.5M
Cash and short-term investments$18M$38.3M$100.7M$153.3M$153.4M
Income statement
20252024202320222021
Revenue$0.00$65.3M$48.8M$40.7M$34.8M
Cost of revenue$370K$0.00$0.00$0.00$1.41M
Gross profit-$-370K$65.3M$48.8M$40.7M$33.4M
Research and development expenses$3.92M$16.6M$52.5M$85.6M$69.4M
Selling, general and administrative expenses$13.5M$23.3M$33.1M$30.5M$24.4M
Other expenses-$-370K$10.9M$0.00$0.00$0.00
Operating expenses$17.1M$50.8M$85.6M$116.2M$93.8M
Cost and expenses$17.5M$50.8M$85.6M$116.2M$95.2M
Interest income$1.03M$3.28M$3.35M$280K$510K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$370K$380K$390K$330K$280K
Ebitda-$-17.09M$25.8M-$-36.38M-$-75.16M-$-41.02M
Operating income-$-17.45M$14.5M-$-36.76M-$-75.48M-$-60.42M
Total other income/expenses, net$1.51M$3.24M$4.93M$21M$19.1M
Income before tax-$-15.95M$17.8M-$-31.84M-$-54.45M-$-41.31M
Income tax expense$0.00$0.00$0.00$0.00$10K
Net income-$-15.95M$17.8M-$-31.84M-$-54.45M-$-41.31M
Weighted average shares outstanding$6.66M$6.66M$6.66M$6.22M$5.63M
Weighted average diluted shares outstanding$6.66M$6.66M$6.66M$6.26M$5.72M
Balance sheet
20252024202320222021
Cash and short-term investments$18M$38.3M$100.7M$153.3M$153.4M
Net receivables$0.00$0.00$90K$10M$7.58M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$18.3M$40.8M$107.5M$167.1M$164.8M
Property, plant and equipment, net$0.00$610K$13.3M$10.7M$9.28M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$610K$13.3M$10.7M$9.28M
Total assets$18.3M$41.4M$120.8M$177.8M$174.1M
Accounts payable$180K$3.17M$6.13M$7.92M$6.36M
Short-term debt$0.00$0.00$1.43M$870K$930K
Deferred revenue$0.00$0.00$320K$4.83M$4.53M
Total current liabilities$1.35M$8.36M$20.3M$24.4M$20.2M
Long-term debt$0.00$0.00$11.3M$8.77M$7.37M
Deferred revenue, non-current$0.00$0.00$64.6M$90.6M$74.7M
Total non-current liabilities$0.00$0.00$75.8M$101M$104.4M
Capital lease obligations$0.00$0.00$12.7M$9.64M$7.37M
Total liabilities$1.35M$8.36M$96.2M$125.4M$124.6M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-404.16M-$-388.22M-$-406M-$-374.16M-$-319.7M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$16.9M$33M$24.6M$52.4M$49.5M
Total investments$0.00$34.6M$83.8M$137.5M$144.9M
Total debt$0.00$0.00$12.7M$9.64M$8.3M
Net debt-$-18.01M-$-3.71M-$-4.18M-$-6.1M-$-240K
Cash flow statement
20252024202320222021
Net income-$-15.95M$17.8M-$-31.84M-$-54.45M-$-41.31M
Depreciation and amortization$370K$380K$390K$330K$280K
Stock-based compensation-$-140K$2.28M$3.59M$8.35M$0.00
Change in working capital-$-4.85M-$-84.28M-$-24.95M$16.9M$16.9M
Accounts receivable$0.00$90K$9.96M-$-2.46M$15.7M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.99M-$-3.15M-$-1.78M$1.56M$3.92M
Net cash provided by operating activities-$-20.84M-$-50.47M-$-52.48M-$-48.75M-$-31.96M
Investments in property, plant and equipment$0.00-$-10K-$-40K-$-480K-$-710K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$35.2M$49.1M$53.7M$6.89M$24.7M
Common stock issued$0.00$0.00$0.00$52.3M$3.47M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-11.66M$0.00$0.00$0.00
Net cash used for financing activities$0.00-$-11.87M-$-40K$49.1M$3.47M
Net change in cash$14.3M-$-13.2M$1.17M$7.2M-$-3.79M
Cash at end of period$18M$3.71M$16.9M$15.7M$8.54M
Operating cash flow-$-20.84M-$-50.47M-$-52.48M-$-48.75M-$-31.96M
Capital expenditure$0.00-$-10K-$-40K-$-480K-$-710K
Free cash flow-$-20.84M-$-50.48M-$-52.52M-$-49.23M-$-32.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lite Strategy, Inc.

        Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.

        CEO
        Justin J. File
        Employees
        4
        Beta
        0.04

        Explore

        Frequently asked questions

        What is the intrinsic value of Lite Strategy, Inc. (LITS)?

        InvestorsCraft does not currently publish an intrinsic value for LITS. How the IC value is calculated.

        Is LITS undervalued?

        InvestorsCraft does not publish an undervaluation signal for LITS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.